open access

Vol 63, No 2 (2013)
Guidelines / Expert consensus
Published online: 2013-06-10
Get Citation

Recommendations for diagnostics and therapy of cutaneous melanoma

Piotr Rutkowski, Piotr J. Wysocki, Zbigniew I. Nowecki, Lidia Rudnicka, Anna Nasierowska-Guttmejer, Jacek Fijuth, Ewa Kalinka-Warzocha, Tomasz Świtaj, Marek Wojtukiewicz, Wojciech Zegarski, Arkadiusz Jeziorski, Krzysztof Krzemieniecki, Renata Zaucha, Emilia Filipczyk-Cisarż, Krzysztof Herman, Maciej Krzakowski
Nowotwory. Journal of Oncology 2013;63(2):157-170.

open access

Vol 63, No 2 (2013)
Recommendations
Published online: 2013-06-10

Abstract

The classic criteria for clinical diagnosis of cutaneous melanoma are: asymmetry of the lesion, irregularity of the border,
colour heterogeneity and diameter of more than 5 mm. Current data show that over 50% of melanomas do not fulfi ll
these criteria. Thus, dermoscopy is currently the standard method for clinical diff erential diagnosis of cutaneous melanoma
and for qualifying a lesion for excisional biopsy. Full thickness excisional biopsy of suspicious melanomatous
skin lesions likely to be diagnosed as early melanomas is crucial in establishing diagnosis and defi ning prognostic factors. Early diagnosis and surgical removal of cutaneous melanoma not only improves patients’ prognosis, but it
is also associated with a approximately 90% likelihood of cure. The next steps in the therapeutic management of
cutaneous melanoma following excisional biopsy are radical scar excision with adequate margins and sentinel lymph
node biopsy. Radical lymph node dissection is recommended in case of regional lymph node metastases. High-risk
patients (lymph node involvement and/or ulcerated primary lesion) should be advised to participate in prospective
clinical trials on adjuvant therapy. Melanoma patients with distant metastases are still characterised by poor outcomes.
In patients with metastatic disease testing for the presence of BRAF gene mutation is recommended. Long-term
survival is confi ned to selected group of patients undergoing resection of isolated metastatic lesions. In systemic
— mainly fi rst-line — therapy of patients with BRAF V600 mutation vemurafenib (BRAF inhibitor) may be employed
and in second-line treatment — based on indication approved in Europe — ipilimumab (anti-CTLA4 antibody) may
be used. Dacarbazine-based chemotherapy is less eff ective.

Abstract

The classic criteria for clinical diagnosis of cutaneous melanoma are: asymmetry of the lesion, irregularity of the border,
colour heterogeneity and diameter of more than 5 mm. Current data show that over 50% of melanomas do not fulfi ll
these criteria. Thus, dermoscopy is currently the standard method for clinical diff erential diagnosis of cutaneous melanoma
and for qualifying a lesion for excisional biopsy. Full thickness excisional biopsy of suspicious melanomatous
skin lesions likely to be diagnosed as early melanomas is crucial in establishing diagnosis and defi ning prognostic factors. Early diagnosis and surgical removal of cutaneous melanoma not only improves patients’ prognosis, but it
is also associated with a approximately 90% likelihood of cure. The next steps in the therapeutic management of
cutaneous melanoma following excisional biopsy are radical scar excision with adequate margins and sentinel lymph
node biopsy. Radical lymph node dissection is recommended in case of regional lymph node metastases. High-risk
patients (lymph node involvement and/or ulcerated primary lesion) should be advised to participate in prospective
clinical trials on adjuvant therapy. Melanoma patients with distant metastases are still characterised by poor outcomes.
In patients with metastatic disease testing for the presence of BRAF gene mutation is recommended. Long-term
survival is confi ned to selected group of patients undergoing resection of isolated metastatic lesions. In systemic
— mainly fi rst-line — therapy of patients with BRAF V600 mutation vemurafenib (BRAF inhibitor) may be employed
and in second-line treatment — based on indication approved in Europe — ipilimumab (anti-CTLA4 antibody) may
be used. Dacarbazine-based chemotherapy is less eff ective.
Get Citation
About this article
Title

Recommendations for diagnostics and therapy of cutaneous melanoma

Journal

Nowotwory. Journal of Oncology

Issue

Vol 63, No 2 (2013)

Article type

Guidelines / Expert consensus

Pages

157-170

Published online

2013-06-10

Page views

629

Article views/downloads

977

Bibliographic record

Nowotwory. Journal of Oncology 2013;63(2):157-170.

Authors

Piotr Rutkowski
Piotr J. Wysocki
Zbigniew I. Nowecki
Lidia Rudnicka
Anna Nasierowska-Guttmejer
Jacek Fijuth
Ewa Kalinka-Warzocha
Tomasz Świtaj
Marek Wojtukiewicz
Wojciech Zegarski
Arkadiusz Jeziorski
Krzysztof Krzemieniecki
Renata Zaucha
Emilia Filipczyk-Cisarż
Krzysztof Herman
Maciej Krzakowski

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl